Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. https://www.reportscorner.com/reports/23243/Esophageal-Cancer-%E2%80%93-Pipeline-Review,-H1-2013/

1. RC
Reports Corner
Esophageal Cancer – Pipeline Review, H1 2013

2. DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H1
2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Esophageal Cancer, complete with latest
updates, and special features on late-stage and discontinued
projects.

3. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H1
2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Esophageal Cancer, complete with latest
updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic
development for Esophageal Cancer. Esophageal Cancer -
Pipeline Review, Half Year is built using data and information
sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources, put together by Global
Markets Direct's team.
Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated
disease.

4. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope
- A snapshot of the global therapeutic scenario for Esophageal
Cancer.
- A review of the Esophageal Cancer products under development
by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development
ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Esophageal Cancer pipeline on the basis of
route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

5. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Identify and understand important and diverse types of
therapeutics under development for Esophageal Cancer.
- Identify emerging players with potentially strong product
portfolio and design effective counter-strategies to gain
competitive advantage.
- Plan mergers and acquisitions effectively by identifying players
of the most promising pipeline.
- Devise corrective measures for pipeline projects by
understanding Esophageal Cancer pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.

6. Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline.

7. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Esophageal Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Esophageal Cancer 11
Esophageal Cancer Therapeutics under Development by Companies 13
Esophageal Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18

8. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Esophageal Cancer Therapeutics – Products under Development by Companies 21
Esophageal Cancer Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Esophageal Cancer Therapeutics Development 24
Bristol-Myers Squibb Company 24
Shionogi & Co., Ltd. 25
Tekmira Pharmaceuticals Corp. 26
Bavarian Nordic A/S 27
Gilead Sciences, Inc. 28
Novartis AG 29
Cell Therapeutics, Inc. 30
Takara Bio Inc. 31

9. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Synta Pharmaceuticals Corp. 32
Transgene Biotek Ltd 33
Proteo, Inc. 34
Supratek Pharma Inc. 35
GANYMED Pharmaceuticals AG 36
Advantagene, Inc. 37
Merrimack Pharmaceuticals, Inc. 38
Omeros Corporation 39
BioStar Pharmaceuticals, Inc. 40
Kringle Pharma, Inc. 41
ImmunoFrontier, Inc. 42
RECEPTA Biopharma S.A. 43
Esophageal Cancer – Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45

10. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
brivanib alaninate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
paclitaxel poliglumex - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BMS-833923 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57

11. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
panobinostat - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ganetespib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
doxorubicin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Elafin - Drug Profile 70
Product Description 70
Mechanism of Action 70

12. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 70
NK-4 Protein - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MM-111 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
IMAB-362 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
celecoxib + [cisplatin] + [irinotecan hydrochloride] + Radiation Therapy - Drug Profile 76
Product Description 76

13. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 76
R&D Progress 76
bevacizumab + [docetaxel] + [oxaliplatin] - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
nimotuzumab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
nimotuzumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
IMF-001 - Drug Profile 84

14. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 84
Mechanism of Action 84
R&D Progress 84
bevacizumab + [capecitabine] + [oxaliplatin] - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
nedaplatin + [docetaxel] - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Peptide Vaccine + [cisplatin] + [fluorouracil ] + [Montanide ISA-51] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88

15. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Peptide Cancer Vaccine + [basiliximab] - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TCR Gene Therapy - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TKM-PLK1 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] + [leucovorin calcium] - Drug Profile 93
Product Description 93
Mechanism of Action 93

16. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
R&D Progress 93
bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
NEO-201 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Autologous Tumor Cell Vaccine + [celecoxib] + [Iscomatrix] - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
GPR39 Antagonist - Drug Profile 98
Product Description 98

17. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Mechanism of Action 98
R&D Progress 98
TBL-0805E - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Drug For Esophageal Cancer - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Xiao'aiping - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
First Generation Attenuated Strain Of Reovirus - Drug Profile 102

18. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Product Description 102
Mechanism of Action 102
R&D Progress 102
Esophageal Cancer Therapeutics – Drug Profile Updates 103
Esophageal Cancer Therapeutics – Discontinued Products 122
Esophageal Cancer Therapeutics - Dormant Products 123
Esophageal Cancer – Product Development Milestones 126
Featured News & Press Releases 126
May 15, 2013: Synta Pharma Announces Presentations On Ganetespib Clinical Trials At 2013 ASCO
Annual Meeting 126
Oct 25, 2012: Novelos Announces Enrollment Of First Patient In Solid Tumor Imaging Trial With I-124-
CLR1404 At University Of Wisconsin Carbone Cancer Center 127
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Results Of MM-111 At European Society for
Medical Oncology 2012 127
Oct 01, 2012: MethylGene Presents Clinical Data On MGCD265 At European Society For Medical Oncology
2012 Congress 129

19. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Jun 08, 2012: Cancer Research UK Launches Trial Of Experimental Drug Combination For Advanced
Stomach And Oesophageal Cancer 130
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute
131
Feb 23, 2011: Proteo's Elafin Shortens Intensive Care After Surgery For Esophagus Cancer 132
Feb 23, 2011: CTI Announces Publication Of Phase II Study Results Of OPAXIO In American Journal Of
Clinical Oncology 132
Jul 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of Complete Response With Low Rate Of
Side Effects In Patients With Advanced Esophageal Cancer 133
Feb 04, 2010: Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation For Elafin In The Treatment Of
Oesophagus Carcinoma 134
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135

20. Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Contact Us 136
Disclaimer 136

21. For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website
https://www.reportscorner.com/reports/23243/Esophageal-Cancer-%E2%80%93-
Pipeline-Review,-H1-2013/

22. Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com